A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377 · ALMOND Phase 2/3Active, not recruiting
- Lead sponsor
- BeOne Medicines (Industry)
- Enrollment
- 178 (actual)
- Start date
- 17 Apr 2023
- Primary completion
- Oct 2027 (estimated)
- Study completion
- 1 Oct 2027
- Last update posted
- 11 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 4
Interventions
- Zanubrutinib Drug
- Tacrolimus Drug
Conditions and primary outcome
- Primary Membranous Nephropathy
Primary outcome
Part 1: Change from Baseline in Urine Protein Creatinine Ratio (UPCR) (Baseline and Week 24); Part 2: Number of Participants Achieving Complete Remission (Week 104)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedTargeting B Cells and Plasma Cells in Glomerular Disease.
Journal of the American Society of Nephrology : JASN · 2025 Jun 4
PubMed 40465397 (opens in a new tab)DOI 10.1681/ASN.0000000772 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT05707377 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.